Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 6,28€(−21,40%). Der Median liegt bei 5,56€(−30,41%).
Kaufen | 5 |
Halten | 2 |
Verkaufen | 4 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Silver Scott Health, Inc. to Offer DNA Vibe's Award-Winning Patented Light Therapy Devices
Division of Silver Scott Mines, Inc. Expands Health and Wellness Offerings FRANKLIN, NJ / ACCESS Newswire / June 24, 2025 / Silver Scott Health, Inc., a division of Silver Scott Mines, Inc. (OTC PINK:SILS), today announced a distribution agreement with DNA Vibe, the innovator behind patented red light therapy devices. Beginning in the third quarter, DNA Vibe's wearable wellness technology will be available for purchase on the Silver Scott Health website, furthering the company's mission to bring scientifically-backed, non-invasive health and wellness solutions to consumers.» Mehr auf accessnewswire.com
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term.» Mehr auf accessnewswire.com
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 44,66 Mio | 27,04% |
Bruttoeinkommen | 33,53 Mio | 127,96% |
Nettoeinkommen | −84,08 Mio | 45,31% |
EBITDA | −63,16 Mio | 58,72% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 481,16 Mio€ |
Anzahl Aktien | 58,53 Mio |
52 Wochen-Hoch/Tief | 14,41€ - 4,28€ |
Dividenden | Nein |
Beta | 1,26 |
KGV (PE Ratio) | −1,10 |
KGWV (PEG Ratio) | −0,07 |
KBV (PB Ratio) | 0,81 |
KUV (PS Ratio) | 2,37 |
Unternehmensprofil
Name | Ginkgo Bioworks Holdings A Aktie |
CEO | Jason Kelly |
Mitarbeiter | 834 |
Assets entdecken
Shareholder von Ginkgo Bioworks Holdings A Aktie investieren auch in folgende Assets